The prevalence of KRAS mutation in colorectal cancer patients in Iranian population: A systematic review and meta-analysis study

Babak Shazad,Edris Sadeghi,Malihe Dayani,Masoud Sadeghi,Mehrdad Payandeh,Nasrin Amirifard,Negin Farshchian

doi:10.15419/bmrat.v4i10.374

Abstract

Colorectal cancer (CRC) is one of the most common cancers in the World that KRAS mutations are considered as a key step in the progression of CRC. This meta-analysis study aimed to evaluate the prevalence of KRAS mutations in CRC patients in Iran. Six online databases including PubMed, Science direct, Scopus, Web of science, Cochran Library, and Scientific Information Database (SID) were searched systematically up to January 2017. A random-effects meta-analysis was used to calculate the estimation of the prevalence of KRAS mutations in CRC patients by the event rate (ER) with 95% confidence interval (95%CI). Out of 82 articles identified from the search, eleven studies included and analyzed for meta-analysis study. The studies included 1814 CRC patients that mean age of the patients was 57.5 years. The pooled ER of the studies for estimation of the prevalence of KRAS mutation in CRC patients was 32.8% (95%CI=28.7-37.3%). The pooled ER of the studies for the prevalence of codon 12 mutation was 72.5% (95%CI=59.8-82.3%) and for codon 13 mutation was 20% (95%CI=14.6-26.7%). The results showed that the prevalence of KRAS mutation in Iran was different with more studies that therefore the geographical area and race can impact on the prevalence of KRAS mutation in CRC patients. Also, codon 12 had the most prevalence among mutant codons, followed by codon 13 that Gly to Asp and Gly to Val were the most mutations in codon 12.  Peer Review Details      Peer review method: Single-Blind (Peer-reviewers: 02) Peer-review policy  Plagiarism software screening?: Yes Date of Original Submission: 07 September 2017 Date accepted: 02 October 2017 Peer reviewers approved by: Dr. Lili Hami  Editor who approved publication: Dr. Phuc Van Pham     

Highlights

Colorectal cancer (CRC) is the fourth most common cancer in men and the third most common in women (Amirifard et al, 2016)
From the initial 82 articles identified from the search, after excluding the studies, 18 studies were assessed for eligibility
Six studies were studied from Tehran (Central of Iran) (Bishehsari et al, 2006; Roudbari et al, 2016; Shemirani et al, 2011; Sobhani et al, 2010; Tameshkel et al, 2016; Vakil et al, 2016), one study from Shiraz (Southwest of Iran) (Omidifar et al, 2015), two studies from Kermanshah (Western of Iran) (Amirifard et al, 2016; Payandeh et al, 2016), one study from Tabriz (Northwestern of Iran) (Dolatkhah et al, 2016), and one study from South Khorasan (Eastern of Iran) (Naseri et al, 2016)

Summary

Introduction

Colorectal cancer (CRC) is the fourth most common cancer in men and the third most common in women (Amirifard et al, 2016). KRAS is a proto-oncogene located on the short arm of chromosome 12, encodes the protein KRAS, a GTPase involved in cell division, differentiation and apoptosis (Dobre et al, 2015). The prevalence of KRAS mutation in CRC patients is 35–40 %, and the majority of these mutations occur in codon and less frequently in codon of KRAS gene (Rosty et al, 2013). The most regularly found kinds of mutations are G>A and G>T transitions (Palmirotta et al, 2009). This meta-analysis study aimed to indicate the prevalence of KRAS mutations in CRC patients in Iran

Methods

Results

Conclusion